Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Smallpox drug put to the test in healthy volunteers

NCT ID NCT02474589

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing an antiviral drug called tecovirimat to see if it is safe and well tolerated when taken by mouth for 14 days. The trial enrolls healthy adults aged 18 to 80 and compares tecovirimat with a placebo. The goal is to gather safety information that could support the drug as a defense against smallpox.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tecovirimat, an antiviral drug
What this could lead to
If it works, this could support tecovirimat as a stockpiled medicine to protect people exposed to smallpox.
What could go wrong
The trial only measures safety and drug levels in healthy volunteers, so it cannot prove the drug prevents or treats smallpox. Side effects may emerge, and animal-rule approval does not guarantee real-world protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

449 people

The number who actually took part.

Started

Jun 2015

Finished

Aug 2016

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 to 80 years old, inclusive * Available for clinical follow-up for the duration of the study * Able and willing to give informed consent * In good general health without clinically significant medical history; not have been hospitalized for a chronic medical condition for the last 2 years * Able to comply with dietary requirements throughout the study drug dosing period * Adequate venous access for those individuals participating in PK testing * PE and laboratory results without clinically significant findings within the 14 days before receipt of study drug * Agree not to drink alcohol from the beginning of the Screening Period through the completion of the Day 28 Follow up Visit * Agree not to use any nicotine products, including electronic vapor cigarettes, nicotine patches or nicotine gum for at least 30 days before the Day 1 Visit and through completion of the Day 15 Dosing complete Visit * Agree not to consume caffeine during all study visits, including overnight stays if participating in PK subset * Agree not to receive any immunizations/vaccinations * Agree not to take herbal products * Able and willing to refrain from taking any prescriptions and nonprescription medications with exceptions * For women of childbearing potential, negative serum and urine pregnancy testing * If male, agree not to donate sperm * Meet 1 of the following criteria: The subject or their partner has undergone surgical sterilization; the subject is postmenopausal; the subject agrees to be abstinent; the subject agrees to consistently use a method of approved birth control. Exclusion Criteria: * Pregnant or breast-feeding or planning pregnancy * Have a history of any clinically significant conditions * Have any limitation of activity related to cardiac disease * Have a bleeding disorder diagnosed by a doctor, or a history of significant bruising or bleeding with intramuscular injections or blood draws * Currently using certain medications * Have a malignancy that is active or a treated malignancy for which there is no reasonable assurance of sustained cure, or malignancy that is likely to recur during the study * Have a history of seizure * Have a clinically significant blood dyscrasia * Have a history of drug allergy that contraindicates participation in the trial * Have a medical, psychiatric, or social condition or any occupational reason, or other responsibility that in the judgment of the investigator would render the subject unable to comply with the protocol * Have an inability to swallow medication * Have a clinically significant abnormal ECG * Have participated in a clinical trials within 30 days of study entry or planning to participate in any experimental treatment study during the study period * Have a history or current drug or alcohol abuse * Have received immunizations/vaccines * Have a current clinically significant acute bacterial, fungal, or mycobacterial infection requiring administration of systemic antibiotics * Have known chronic bacterial, mycobacterial, fungal, parasitic, or protozoal infection with the exception of clinically significant dermal infections * Have known hepatitis B or C infection, or positive test result * Have known HIV infection or AIDS or a positive test for HIV * Have a current clinically significant viral infection * Have known clinically significant chronic viral infection * have received treatment with greater than 20 mg prednisone or equivalent dose or any immunosuppressant or immunomodulary medication * Have abnormal laboratory testing during screening * Have a greater than or equal than 20% risk of suffering a major cardiovascular event * Have been previously enrolled in this or any clinical trial involving tecovirimat

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Smallpox are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Benchmark Research

    Austin, Texas, 78705, United States

  • Benchmark Research

    Fort Worth, Texas, 76135, United States

  • Center for Pharmaceutical Research

    Kansas City, Missouri, 64114, United States

  • Coastal Clinical Research, Inc.

    Mobile, Alabama, 36608, United States

  • Heartland Research Associates, LLC

    Newton, Kansas, 67114, United States

  • Johnson County Clinical Trials

    Lenexa, Kansas, 66219, United States

  • Medical Research South

    Charleston, South Carolina, 29407, United States

  • Meridien Clinical Research

    Omaha, Nebraska, 68134, United States

  • Paradigm Research

    Redding, California, 96001, United States

  • Paradigm Research

    San Diego, California, 92117, United States

  • Sundance Clinical Research LLC

    St Louis, Missouri, 63141, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.